|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| CURRENT ASSETS | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Short-term investments | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total prepaid expenses and other current assets | ||||||||||||||||||||
| Current assets of discontinued operations | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| GeneFab receivable - related party, net of current portion | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| GeneFab Economic Share - related party | ||||||||||||||||||||
| Other non-current assets | ||||||||||||||||||||
| Noncurrent assets of discontinued operations | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||||||||||||||||||||
| CURRENT LIABILITIES | ||||||||||||||||||||
| Franchise tax payable | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Finance lease liabilities - related party, current portion | ||||||||||||||||||||
| Total finance lease liabilities - related party, current portion | ||||||||||||||||||||
| Early exercise liability, current portion | ||||||||||||||||||||
| Accrued expenses and other current liabilities | ||||||||||||||||||||
| Convertible notes - related party | ||||||||||||||||||||
| Operating lease liabilities, current | ||||||||||||||||||||
| Contingent earnout liability | ||||||||||||||||||||
| Current liabilities of discontinued operations | ||||||||||||||||||||
| GeneFab sublease deferred income - related party | ||||||||||||||||||||
| Deferred revenue - related party | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Finance lease liabilities, net of current portion | ||||||||||||||||||||
| Total finance lease liabilities, net of current portion | ||||||||||||||||||||
| Operating lease liabilities, non-current | ||||||||||||||||||||
| Contingent earnout liability | ||||||||||||||||||||
| GeneFab Option - related party | ||||||||||||||||||||
| Early exercise liability, net of current portion | ||||||||||||||||||||
| Other non-current liabilities | ||||||||||||||||||||
| TOTAL LIABILITIES | ||||||||||||||||||||
| Series A redeemable convertible preferred stock, $0.0001 par value; zero and 21,200 shares authorized as of December 31, 2025 and 2024, respectively; zero and 21,157 shares issued and outstanding as of December 31, 2025 and 2024, respectively; aggregate liquidation preference of zero and $147,647 as of December 31, 2025 and 2024, respectively | ||||||||||||||||||||
| STOCKHOLDERS’ EQUITY (DEFICIT) | ||||||||||||||||||||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized at September 30, 2024 and December 31, 2023; zero shares issued and outstanding at September 30, 2024 and December 31, 2023 | ||||||||||||||||||||
| Common stock, $0.0001 par value; 500,000,000 shares authorized as of both June 30, 2026 and December 31, 2025; 31,144,754 and 30,879,355 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Total common stock, $0.0001 par value; 500,000,000 shares authorized as of both June 30, 2026 and December 31, 2025; 31,144,754 and 30,879,355 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive income | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| TOTAL STOCKHOLDERS’ EQUITY (DEFICIT) | ||||||||||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||||||||||||||||||||
| Preferred stock, shares issued (in shares) | ||||||||||||||||||||
| Preferred stock, shares outstanding (in shares) | ||||||||||||||||||||
| Series A redeemable convertible preferred stock, shares authorized (in shares) | ||||||||||||||||||||
Loading...
